A study of correlation between tumor marker (HER-2/neu & SCCA) and oral squamous cell carcinoma
碩士 === 高雄醫學大學 === 牙醫學研究所碩士班 === 92 === abstract Overexpression of c-erbB-2（also known as HER-2/neu）has been found in many human cancers,including head and neck squamous cell carcinoma. HER-2/neu overexpression has been associated with advanced disease, metastasis, and poor clinical outcome in breast...
| Main Authors: | , |
|---|---|
| Other Authors: | |
| Format: | Others |
| Language: | zh-TW |
| Published: |
2004
|
| Online Access: | http://ndltd.ncl.edu.tw/handle/46499879381608424378 |
| Summary: | 碩士 === 高雄醫學大學 === 牙醫學研究所碩士班 === 92 === abstract
Overexpression of c-erbB-2（also known as HER-2/neu）has been found in many human cancers,including head and neck squamous cell carcinoma. HER-2/neu overexpression has been associated with advanced disease, metastasis, and poor clinical outcome in breast <a href="http://www.ntsearch.com/search.php?q=cancer&v=56">cancer</a>. Squamous cell carcinoma associasted antigen is widely used as a tumor marker in a broad variety of carcinomas of squamous cell origin in different body sites. Purpose of this study was to investigate the pre-treatment and post-treatment values of HER-2/neu and SCCA in patients treated for oral squamous cell carcinoma. Materials and methods: 46 patients with primary OSCC were obtained from the Department of Oral and Maxillofacial Surgery, Chung-Ho Memorial Hospital, Kaohsiung <a href="http://www.ntsearch.com/search.php?q=Medical&v=56">Medical</a> <a href="http://www.ntsearch.com/search.php?q=University&v=56">University</a> between 2003 and 2004. Serum samples were obtained before treatment and at intervals following treatment. HER-2/neu levels were determined by Enzyme-linked Immunosorbant Assay（ELISA） and SCCA levels were determined by Radioimmunoassay（RIA）. Significant correlation was found between HER-2/neu and lymph node metastasis（p=0.0017）. SCCA was also correlated with tumor size（p=0.0254）.Both HER-2/neu and SCCA could obtain a significant mean reduction after treatment. We chose the 95% level of normal controls as a cut-off to distinguish individuals with elevated levels. The number of OSCC (65%) with an elevated serum HER-2/neu protein level was significantly greater than that of the control group. The combination of HER-2/neu and SCCA significantly improved yhe predicting power. Conclusion: HER-2/neu and SCCA may be a useful marker in evaluating therapeutic effects and in monitoring the recurrence status of oral squamous cell carcinoma.
|
|---|